Tracking babies born to mothers on rare disease drug
NCT ID NCT05040373
Summary
This study aims to collect information about pregnancy outcomes in women who took patisiran-LNP medication for hereditary amyloidosis. Researchers will track birth defects, pregnancy complications, and infant health. The goal is to understand the safety of this medication during pregnancy by observing real-world outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY TRANSTHYRETIN-MEDIATED (HATTR) AMYLOIDOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Trial Site
RECRUITINGIowa City, Iowa, 52242, United States
-
Clinical Trial Site
RECRUITINGNantes, France
-
Clinical Trial Site
RECRUITINGMünster, Germany
-
Clinical Trial Site
RECRUITINGPavia, Italy
-
Clinical Trial Site
RECRUITINGGroningen, Netherlands
-
Clinical Trial Site
RECRUITINGLisbon, Portugal
-
Clinical Trial Site
RECRUITINGMadrid, Spain
Conditions
Explore the condition pages connected to this study.